High-Content Assays for Characterizing the Viability and Morphology of 3D Cancer Spheroid Cultures

Assay and Drug Development Technologies

Volumn 13, Issue 7, 2015, Pages 402-414

  Sirenko, Oksana ^a   Mitlo, Trisha ^a   Hesley, Jayne ^a   Luke, Steve ^a   Owens, Windsor ^a   Cromwell, Evan F ^b  

^a MOLECULAR DEVICES CORPORATION   (United States)

^b Protein Fluidics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ETOPOSIDE; MITOMYCIN; PACLITAXEL; STAUROSPORINE; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL ASSAY; CELL COUNT; CELL PROLIFERATION; CELL SHAPE; CELL SIZE; CELL STRUCTURE; CELL VIABILITY; CELL VIABILITY ASSAY; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPE; CONTROLLED STUDY; CYTOMETRY; DU145 CELL LINE; FLUORESCENCE MICROSCOPE; HCT116 CELL LINE; HEPG2 CELL LINE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC50; IMAGE ANALYSIS; IMAGING SOFTWARE; IMAGING SYSTEM; MALE; MOLECULAR IMAGING; PHENOTYPE; PHENOTYPIC VARIATION; PROSTATE CANCER CELL LINE; SINGLE CELL ANALYSIS; STAINING; THREE DIMENSIONAL IMAGING; TUMOR MODEL; TUMOR SPHEROID; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; MULTICELLULAR SPHEROID; PROCEDURES; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PHENOTYPE; SPHEROIDS, CELLULAR;

EID: 84940653267     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2015.655     Document Type: Article

References (38)

1. Kunz-Schughart LA, Freyer JP, Hofstaedter F, et al.: The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen 2004;9:273-285.
2. Mueller-Klieser W. Three-dimensional cell cultures: from molecular mechanisms to clinical applications. Am J Physiol 1997;273:C1109-C1123.
3. Wartenberg M, Donmez F, Ling FC, et al.: Tumor-induced angiogenesis studied in confrontation cultures of multicellular tumor spheroids and embryoid bodies grown from pluripotent embryonic stem cells. FASEB J 2001;15:995-1005.
4. Frieboes HB, Zheng X, Sun CH, et al.: An integrated computational/experimental model of tumor invasion. Cancer Res 2006;66:1597-1604.
5. Wenzel C, Riefke B, Grundemann S, et al.: 3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions. Exp Cell Res 2014;323:131-143.
6. Calcagno AM, Salcido CD, Gillet JP, et al.: Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst 2010;102:1637-1652.
7. Ponti D, Costa A, Zaffaroni N, et al.: Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005;65:5506-5511.
8. Thoma CR, Stroebel S, Rosch N, et al.: A high-throughput-compatible 3D microtissue co-culture system for phenotypic RNAi screening applications. J Biomol Screen 2013;18:1330-1337.
9. Ramsden D, Tweedie DJ, Chan TS, et al.: Bridging in vitro and in vivo metabolism and transport of faldaprevir in human using a novel cocultured human hepatocyte system, HepatoPac. Drug Metab Dispos 2014;42:394-406.
10. Bhadriraju K, Chen CS. Engineering cellular microenvironments to improve cell-based drug testing. Drug Discov Today 2002;7:612-620.
11. Lin RZ, Chang HY. Recent advances in three-dimensional multicellular spheroid culture for biomedical research. Biotechnol J 2008;3:1172-1184.
12. Tung YC, Hsiao AY, Allen SG, et al.: High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array. Analyst 2011;136:473-478.
13. Wang Y, Wang J. Mixed hydrogel bead-based tumor spheroid formation and anticancer drug testing. Analyst 2014;139:2449-2458.
14. Montanez-Sauri SI, Sung KE, Berthier E, et al.: Enabling screening in 3D microenvironments: probing matrix and stromal effects on the morphology and proliferation of T47D breast carcinoma cells. Integr Biol (Camb) 2013;5:631-640.
15. Fukuda J, Khademhosseini A, Yeo Y, et al.: Micromolding of photocrosslinkable chitosan hydrogel for spheroid microarray and co-cultures. Biomaterials 2006;27:5259-5267.
16. Wang W, Itaka K, Ohba S, et al.: 3D spheroid culture system on micropatterned substrates for improved differentiation efficiency of multipotent mesenchymal stem cells. Biomaterials 2009;30:2705-2715.
17. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol 2014;32:760-772.
18. Vinci M, Gowan S, Boxall F, et al.: Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol 2012;10:29.
19. Krausz E, de Hoogt R, Gustin E, et al.: Translation of a tumor microenvironment mimicking 3D tumor growth co-culture assay platform to high-content screening. J Biomol Screen 2013;18:54-66.
20. Horman SR, To J, Orth AP. An HTS-compatible 3D colony formation assay to identify tumor-specific chemotherapeutics. J Biomol Screen 2013;18:1298-1308.
21. Herrmann R, Fayad W, Schwarz S, et al.: Screening for compounds that induce apoptosis of cancer cells grown as multicellular spheroids. J Biomol Screen 2008;13:1-8.
22. Waite CL, Roth CM. PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma. Bioconjug Chem 2009;20:1908-1916.
23. Drewitz M, Helbling M, Fried N, et al.: Towards automated production and drug sensitivity testing using scaffold-free spherical tumor microtissues. Biotechnol J 2011;6:1488-1496.
24. Sirenko O, Hesley J, Rusyn I, et al.: High-content assays for hepatotoxicity using induced pluripotent stem cell-derived cells. Assay Drug Dev Technol 2014;12:43-54.
25. Achilli TM, McCalla S, Meyer J, et al.: Multilayer spheroids to quantify drug uptake and diffusion in 3D. Mol Pharm 2014;11:2071-2081.
26. Hama H, Kurokawa H, Kawano H, et al.: Scale: a chemical approach for fluorescence imaging and reconstruction of transparent mouse brain. Nat Neurosci 2011;14:1481-1488.
27. Takeda M, Mizokami A, Mamiya K, et al.: The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate 2007;67:955-967.
28. Hossein G, Zavareh VA, Fard PS. Combined Treatment of Androgen-Independent Prostate Cancer Cell Line DU145 with Chemotherapeutic Agents and Lithium Chloride: Effect on Growth Arrest and/or Apoptosis. Avicenna J Med Biotechnol 2012;4:75-87.
29. Al-Qubaisi M, Rozita R, Yeap SK, et al.: Selective cytotoxicity of goniothalamin against hepatoblastoma HepG2 cells. Molecules 2011;16: 2944-2959.
30. Fallon RJ. Staurosporine inhibits a tyrosine protein kinase in human hepatoma cell membranes. Biochem Biophys Res Commun 1990;170:1191-1196.
31. Chan PK, Aldrich MB, Chakrabarty S. Assessment of tumor cell sensitivity to mitomycin C by "B23 translocation" assay. Cancer Lett 1988;40:143-149.
32. Yang EB, Tang WY, Zhang K, et al.: Norcantharidin inhibits growth of human HepG2 cell-transplanted tumor in nude mice and prolongs host survival. Cancer Lett 1997;117:93-98.
33. Smith V, Raynaud F, Workman P, et al.: Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol. Mol Pharmacol 2001;60:885-893.
34. Khademhosseini A, Langer R, Borenstein J, et al.: Microscale technologies for tissue engineering and biology. Proc Natl Acad Sci U S A 2006;103:2480-2487.
35. Langer R, Tirrell DA. Designing materials for biology and medicine. Nature 2004;428:487-492.
36. Desoize B, Jardillier J. Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol 2000;36:193-207.
37. Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007;130:601-610.
38. Hartung T. Toxicology for the twenty-first century. Nature 2009;460: 208-212.